To the editor: Although the high price of cancer drugs and their marginal benefits (often only weeks to months) have been increasingly criticized, cost-effectiveness analyses (CEAs) often reach favorable conclusions regarding these agents. Recently, Saret and colleagues, using data from the Tufts
No takes yet. Share an insight, caveat, or question.
Prasad et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: